Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Proteomics research aids cancer diagnosis and treatment

11.04.2003


A new technique may allow physicians to monitor patients’ responses to molecularly targeted drugs, according to researchers from the National Cancer Institute (NCI) and the Food and Drug Administration (FDA) *. The finding was one of three advances in proteomics – the study of proteins within cells – scheduled to be announced by researchers from the NCI-FDA Clinical Proteomics Program in a press briefing at the 94th Annual American Association for Cancer Research (AACR) Annual Meeting, which was canceled.



Monitoring Cancer Treatment

In the first study, the researchers successfully identified specific proteins that may be useful in monitoring patients treated for breast or ovarian cancer. Their approach, based on changing levels of active proteins inside tumor cells, could help physicians determine early during treatment whether a particular drug is working effectively for an individual cancer patient.


"The results of our study suggest this approach may help us tailor treatment to individual patients," noted Virginia Espina, M.S., M.T. (ASCP), NCI, the lead investigator on the study.

Because molecularly targeted drugs are designed to target specific molecules that have gone awry in cancer cells, researchers can predict which of the cell’s many complex signaling pathways these drugs are likely to affect. In ongoing studies at NCI, researchers are using proteomic technology to monitor the key pathways likely to be influenced by the molecularly targeted drugs Gleevec®, Herceptin®, and Iressa®.

To monitor changes in tumor cell proteins, the researchers isolated cancer cells from tumor biopsies and measured the level of various proteins involved in the signaling pathways targeted by the drugs. The scientists measured not only the total amount of each protein, but also how much of the protein was in its active form. These proteins were measured prior to treatment and at selected times after treatment.

The researchers found that prior to treatment, patients with breast cancer who had a poor clinical outcome tended to have more of the active form of a protein known as AKT, which promotes cell survival. Treatment with Herceptin®, however, resulted in a change in the relative amount of the active form of AKT, enabling tumor cell death.

"Treatment with Herceptin® appears to alter the level of active AKT in tumors. We may be able to measure the degree of this change in patients who are receiving treatment to determine whether a drug that inhibits this signaling pathway is best for their individual cancer," said Lance Liotta, M.D., Ph.D., co-director of the Clinical Proteomics Program and the senior NCI investigator on the study.

The researchers expect to be able to apply the proteomic approach to monitor the treatment of other cancers with molecularly targeted drugs, but further research is required to identify the best proteins to measure in those tumors.

Diagnosing Ovarian Cancer

In another study, in collaboration with Correlogic Systems Inc., NCI and FDA scientists have improved the NCI/FDA/Correlogic method of ovarian cancer diagnosis currently under evaluation**. The approach uses Correlogic’s artificial intelligence computer programs to analyze the patterns of proteins in the blood and can detect the presence of disease even at early stages. In a previously published study, researchers used the technique to successfully differentiate between blood samples taken from patients with ovarian cancer and those from unaffected individuals.

The researchers discovered patterns of proteins that correctly identify 100 percent of blood samples as being from either unaffected individuals or patients with ovarian cancer. This is an improvement on the previous analysis, which correctly identified 100 percent of the samples from patients with cancer, but only 95 percent of the non-cancer samples. The researchers analyzed the proteins using mass spectroscopy, a technique that sorts proteins and other molecules based on their weight and electrical charge; they attribute the improvement in specificity primarily to the use of a higher resolution mass spectrometer in the most recent study. "The increased resolution allows us to distinguish more features within the patterns generated from the serum samples," said Timothy Veenstra, Ph.D., of the Mass Spectrometry Center at NCI-Frederick.

Visualizing Protein Patterns

The NCI-FDA team has also developed new tools for visualizing and analyzing protein patterns***. Beyond identifying the presence of ovarian cancer and other diseases, these tools may allow researchers to determine how far the disease has progressed by matching specific proteomic patterns to a particular stage.

"The new tools improve upon previous methods of identifying discriminatory protein patterns by allowing researchers to visualize the entire set of proteins in a single view, as well as zoom in and out to focus on regions of interest within the data," said Emanuel Petricoin III, Ph.D., co-director of the Clinical Proteomics Program and the senior FDA researcher on the project.

"Using these visualization tools, the identification of proteomic patterns that aid in disease diagnosis can be done with greater sensitivity and accuracy," said Donald Johann Jr., M.D., of the NCI-FDA Clinical Proteomics Program, lead investigator of the study. "This new method reduces the risk of error, increases our productivity, and provides an efficient method to analyze large sets of protein data.

NCI Press Office | EurekAlert!
Further information:
http://cancer.gov/cancerinfo/digestpage/proteomics
http://cancer.gov/cancerinfo/digestpage/proteomics

More articles from Health and Medicine:

nachricht Collagen nanofibrils in mammalian tissues get stronger with exercise
14.12.2018 | University of Illinois College of Engineering

nachricht New discoveries predict ability to forecast dementia from single molecule
12.12.2018 | UT Southwestern Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Data use draining your battery? Tiny device to speed up memory while also saving power

The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.

Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...

Im Focus: An energy-efficient way to stay warm: Sew high-tech heating patches to your clothes

Personal patches could reduce energy waste in buildings, Rutgers-led study says

What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

Im Focus: Topological material switched off and on for the first time

Key advance for future topological transistors

Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

 
Latest News

Data use draining your battery? Tiny device to speed up memory while also saving power

14.12.2018 | Power and Electrical Engineering

Tangled magnetic fields power cosmic particle accelerators

14.12.2018 | Physics and Astronomy

In search of missing worlds, Hubble finds a fast evaporating exoplanet

14.12.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>